Loading

logo

Journal of Physical Medicine and Rehabilitation

ISSN: 2690-0297

Review Article Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/rehabilitation.3.022

The Use of Consumer Wearable Physical Activity Monitors in Clinical Populations with Functional L imitations

Julian Martinez1, *, Taylor M. Gordon1, Scott J. Strath1
  • 1Department of Kinesiology, University of Wisconsin-Milwaukee, Milwaukee, WI 53201-0413, USA
+ Affiliations - Affiliations

Corresponding Author

Julian Martinez, marti994@uwm.edu

Received Date: October 01, 2021

Accepted Date: November 16, 2021

Citation:

Martinez J, Gordon TM, Strath SJ. The Use of Consumer Wearable Physical Activity Monitors in Clinical Populations with Functional Limitations. J Phys Med Rehabil 2021; 3(2): 73-90.


Copyright: © 2021 Martinez J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Functionally limiting health conditions have a high rate of prevalence worldwide and incur a significant amount of economic burden. Physical activity (PA) can prevent the onset of these conditions and alleviate economic burden by reducing symptoms, but a large portion of these individuals do not engage in health enhancing PA. Consumer wearable physical activity monitors (WPAM) are tools that have become increasingly popular within the past few years and could provide a means to improve PA levels for individuals with health conditions that cause functional limitations. This review reports on the validity of PA outcomes, feasibility and utility, and intervention/promotion effectiveness for consumer WPAM in functionally limited clinical populations. 2250 records from January 2018 to July 2021 were retrieved from PubMed, Web of Science, SPORTDiscus and CINAHL with 656 records being duplicates and 23 records passing a full-text article review. Studies included within the review looked at individuals with osteoarthritis, rheumatoid arthritis, axial spondyloarthritis, multiple sclerosis, Parkinson’s disease, ischemic stroke and peripheral arterial disease. The most popular brand of consumer WPAM was Fitbit. Validation studies for consumer WPAM were primarily focused on step counts showing overestimations for daily step counts and over- and under-estimations occurring within shorter time durations depending on step cadence. Wrist worn WPAM are the most feasible for functionally limited clinical populations with widespread utilization for associating clinically relevant outcomes with PA levels but they have limited validation to confirm their accuracy and precision in measurement. Interventions included used a mixture of a WPAM and other behavior change techniques to improve PA levels for clinical populations and show promising effectiveness. Future work is warranted on determining the validity of PA outcomes from WPAM determined to be feasible in select clinical populations and creating interventions looking at which features of a consumer WPAM intervention promote PA.

Keywords

Physical Activity, Activity Monitor, Fitbit, Arthritis, Multiple Sclerosis, Parkinson’s, Stroke

Recommended Articles

Recent Advances Show That Abnormal T-Regulatory Cell Function Perpetuates Chronic Inflammatory Arthritis

The principal mechanism governing immune central tolerance is regulated by T-cells that reside in a pathway wherein the death of immature T-cells is coupled to the development of CD4+ regulatory T (Treg) cells. In that regard, Treg cells undergo development in the thymus or peripheral tissues upon recognition of self-antigens.

The Use of Consumer Wearable Physical Activity Monitors in Clinical Populations with Functional L imitations

The prevalence of many musculoskeletal and cardiovascular diseases that cause limitations in physical functioning has increased globally [1] with age-adjusted rates of incidence rising for many of these diseases [2-5]. In the United States alone, chronic health conditions that limit physical function have an estimated economic impact of $200

Cutaneous Side Effects of First-Second Line Oral Disease - Modifying Treatments in Patients with Multiple Sclerosis

Multiple sclerosis (MS) is a progressive autoimmune and sometimes disabling disease of the central nervous system (CNS), characterized by formation of white matter lesions in the CNS due to inflammation, demyelination and axonal loss [1-3]. 

Is Cellular Senescence of Dopaminergic Neurons the Cause of Local Inflammation in the Midbrain Observed in Parkinson’s Disease?

Current research investigating the pathomechanisms of neurodegenerative disorders of the central nervous system (CNS), such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), or Parkinson’s disease (PD), led to the understanding that these diseases have to be seen in the context of immune responses [1]. In other words,

Maintenance of [Met5]-enkephalin Blood Levels Corresponds with a Positive Outcome in Multiple Sclerosis

Multiple sclerosis (MS) is a debilitating disease with a multifactorial etiology that remains to be fully defined. In the United States alone it is estimated that there are one million individuals living with MS.

Full Text
Cite
Download PDF
Author Information X

About Scientific Archives

Scientific Archives is a global publisher initiated with the mission of ensuring equal opportunity for accessing science to research community all over the world. Spreading research findings with great relevance to all channels without any barrier is our goal. We want to overcome the challenges of Open Access with ensured quality and transparency.

Read More